Top Grade 99% Riociguat CAS: 625115-55-1 for Chronic Thromboembolic Pulmonary Hypertension

Vericiguat​

Bosentan

​​Ambrisentan​​

Macitentan​​

1. Overview and Description:​​

Riociguat (pronounced ree-oh-SIG-yoo-at) is an oral medication classified as a soluble guanylate cyclase (sGC) stimulator. It represents a distinct approach to managing certain types of pulmonary hypertension (PH), a condition characterized by elevated blood pressure within the arteries connecting the heart to the lungs (pulmonary arteries). This high pressure forces the right side of the heart to work much harder, leading to symptoms like shortness of breath, fatigue, dizziness, and swelling, and significantly impacting quality of life. Unlike some other PH medications that primarily act on specific pathways (like prostacyclin analogs or endothelin receptor antagonists), riociguat works by directly targeting a fundamental signaling molecule within the blood vessel cells themselves.

​​2. Mechanism of Action: Enhancing the NO-sGC-cGMP Pathway​​

Activation of sGC:​​ Inside these cells, no binds to an enzyme called soluble guanylate cyclase (sGC). This binding activates sGC.
​​Production of cGMP:​​ Activated sGC produces another signaling molecule called cyclic guanosine monophosphate (cGMP).
​​Relaxation Effect:​​ Increased levels of cGMP trigger a cascade of events inside the smooth muscle cells of the blood vessels, ultimately causing them to relax. This vasodilation (widening of blood vessels) reduces pressure within the pulmonary arteries and improves blood flow.
​​Riociguat's Role:​​ Riociguat has a dual action:
​​Stimulation:​​ It directly stimulates sGC, making the enzyme more active independently of no.
​​Sensitization:​​ It also makes sGC more sensitive to whatever no is present, increasing its ability to produce cGMP when no binds.
​​Essentially, riociguat boosts the levels of cGMP within the pulmonary artery cells. Higher cGMP levels lead to relaxation of these blood vessels, reducing the abnormally high pressure in the pulmonary artery system and easing the workload on the right heart.​​

​​3. Approved Medical Uses:​​

Riociguat is specifically approved for the long-term management of two distinct types of pulmonary hypertension classified under Group 4 and Group 1 by the World Symposium on Pulmonary Hypertension:

​​Chronic Thromboembolic Pulmonary Hypertension (CTEPH) - Group 4:​​
​​The Condition:​​ CTEPH occurs when old blood clots in the pulmonary arteries (pulmonary emboli) do not dissolve completely. Over time, this unresolved clot material transforms into scar-like tissue that physically blocks or narrows the pulmonary arteries. Additionally, the blocked vessels cause the surrounding small pulmonary arteries to constrict abnormally (a process called distal vasculopathy).
​​Riociguat's Use:​​ Riociguat is indicated for ​​adult patients with inoperable CTEPH​​, meaning surgery to physically remove the blockages (pulmonary endarterectomy) is not possible or carries too much risk. It is also approved ​​following surgical treatment (PEA) in adult patients with persistent or recurrent CTEPH​​, where symptoms and elevated pressures remain or return after surgery. By relaxing the pulmonary arteries, particularly the constricted distal vessels, riociguat helps lower pulmonary artery pressure, improve exercise capacity (like walking distance), and reduce symptoms.
​​Pulmonary Arterial Hypertension (PAH) - Group 1:​​
​​The Condition:​​ PAH involves the progressive narrowing of the small pulmonary arteries themselves. This narrowing happens due to excessive cell growth and stiffening within the walls of these arteries. PAH can be idiopathic (unknown cause), heritable, or associated with conditions like connective tissue diseases, HIV infection, or congenital heart defects.
​​Riociguat's Use:​​ Riociguat is indicated for the ​​long-term management of adult patients with PAH to improve exercise ability​​. It can be used as a standalone therapy (​​monotherapy​​) in patients who are not candidates for other specific classes of PAH drugs or when preferred. Importantly, it is ​​not approved for use alongside other drugs that work by inhibiting phosphodiesterase type 5 (PDE5)​​ such as sildenafil or tadalafil, or the soluble guanylate cyclase stimulator (sGCS) vericiguat (used in heart failure), due to significant risks associated with low blood pressure. Its use is sometimes considered in sequential or combination treatment strategies as determined by PH specialists.

​​4. Administration, Dosage, and Properties:​​

​​Form:​​ Riociguat is taken orally in tablet form.
​​Dosing:​​ Treatment requires careful medical supervision. It involves a structured ​​titration phase​​. Starting at a very low dose (e.g., 1.0 mg three times daily), the dose is gradually increased, typically no more than once every one to two weeks, based on individual tolerability (especially concerning blood pressure levels). The goal is to reach an optimal individualized maintenance dose (usually within a specific range per administration) that provides benefit while minimizing potential side effects.
​​Monitoring:​​ Regular monitoring of blood pressure is essential, particularly during the dose adjustment phase. Liver function may also be monitored periodically.
​​Important Considerations:​​ Riociguat interacts with numerous other medications. Crucially, it must not be taken with PDE5 inhibitors (e.g., sildenafil, tadalafil, vardenafil) or other sGC stimulators (e.g., vericiguat). Concomitant use of strong CYP inhibitors (like HIV protease inhibitors, certain antifungals) or CYP inducers (like rifampin) significantly alters riociguat levels and requires dose adjustments or avoidance. Pregnancy is an absolute contraindication due to the risk of severe fetal harm. Effective contraception is mandatory during treatment and for a period afterwards.

​​5. Source and Development:​​

Riociguat was discovered and developed by the pharmaceutical company Bayer AG. Its development was based on research，particularly those involving pulmonary hypertension. The approval for CTEPH and PAH in various regions, including the United States (FDA, 2013), Europe (EMA, 2014), and other countries, followed large-scale clinical studies that demonstrated its benefits in improving important clinical parameters like exercise capacity and pulmonary hemodynamics for eligible patients with these specific conditions.

​​6. Conclusion:​​

Riociguat offers a targeted therapeutic approach for specific forms of pulmonary hypertension: inoperable CTEPH and persistent/recurrent CTEPH post-surgery, and PAH. As an sGC stimulator, it works by enhancing a key cellular pathway responsible for blood vessel relaxation, thereby lowering abnormally high pressure within the pulmonary arteries. This action translates to improvements in functional capacity and symptoms for many patients. Its use requires strict adherence to dosing guidelines, careful monitoring for potential side effects, and absolute avoidance of contraindicated medications. Managed by specialists in pulmonary hypertension, riociguat represents an important option within the treatment landscape for these complex conditions.

.